Is AstraZeneca's Pipeline Fuel Enough to Spark a Post-Earnings Breakout on Oct. 30?24/7 Wall Street • 10/26/26
TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSOBusiness Wire • 10/25/26
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancerBusiness Wire • 10/24/26
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA NephropathyZacks Investment Research • 10/22/26
ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutationsBusiness Wire • 10/22/26
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis StudyBenzinga • 10/20/26
AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinibBusiness Wire • 10/19/26
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness MonthZacks Investment Research • 10/16/26
RBC keeps AstraZeneca at ‘outperform' ahead of AVANZAR lung cancer trialProactive Investors • 10/15/26
AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting TranscriptSeeking Alpha • 10/12/26